Francois Valencony
Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer @ Mérieux Equity Partners
Boston, United States
Francois Valencony is a Series C investor at Mérieux Equity Partners in Boston focused on Health Care and Life Science. Francois Valencony - Managing Partner & Executive Officer @ Mérieux Equity Partners
- Total investments:
- 18
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Francois Valencony invests in
Stages Francois Valencony invests in
Countries Francois Valencony invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (17%)
- Life Science 2 (11%)
- Therapeutics 2 (11%)
- Biotechnology 2 (11%)
- Software 1 (6%)
Stage
- Series C 2 (11%)
- Series B 1 (6%)
- Series D 1 (6%)
- Private Equity 1 (6%)
- Venture - Series Unknown 1 (6%)
Country
- United States 2 (11%)
- Luxembourg 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M / Series C / Apr 04, 2019 | ||
| Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M / Series C / Dec 19, 2018 | ||
| Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $55.5M / Series C / Feb 28, 2018 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $17M / Series D / Mar 25, 2014 | ||
| Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | Venture - Series Unknown / Jun 20, 2013 | ||
| Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | Private Equity / May 27, 2013 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $6.4M / Series C / May 06, 2013 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $9M / Series B / Mar 08, 2012 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $12.4M / Series B / Mar 01, 2011 | ||
| See all 18 investments → | |||
Co-Investors
About Mérieux Equity Partners
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Mérieux Equity Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Francois Valencony
Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer
|
|||
Jean-Francois Billet
Senior Partner
|
|||
Jean-Guillaume Lafay
Operating Partner
|
|||
Thierry Chignon
Senior Partner
|
|||
Valerie Calenda
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Francois Valencony invest in?
Francois Valencony invests primarily in Health Care, Life Science and Therapeutics startups, most often at Series C and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Francois Valencony?
Public channels for Francois Valencony include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Francois Valencony last invest?
The most recent investment recorded for Francois Valencony closed in Apr 2019. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
